02.08.2024, 23:44
The first domestic analogue of insulin "Apidra" is registered in the Russian Federation
Source: OREANDA-NEWS
OREANDA-NEWS The Russian pharmaceutical company Geropharm has registered a new insulin Ringlusin, it is the first Russian biosimilar of the drug Apidra by the French pharmaceutical company Sanofi, the press service of Geropharm told Interfax.
"Geropharm has registered a new insulin "Ringlusin" with the active substance glulisin, which is equal in strength to ordinary human insulin," the message says.
It notes that the drug has passed a complex of studies, clinical trials were conducted in leading research centers in Russia.
Like other Geropharm insulins, Ringluzin will be produced in Russia on the principle of a full cycle - from the substance to the finished dosage form. Production will be carried out at the company's own plants in St. Petersburg and the Moscow region.
"Geropharm has registered a new insulin "Ringlusin" with the active substance glulisin, which is equal in strength to ordinary human insulin," the message says.
It notes that the drug has passed a complex of studies, clinical trials were conducted in leading research centers in Russia.
Like other Geropharm insulins, Ringluzin will be produced in Russia on the principle of a full cycle - from the substance to the finished dosage form. Production will be carried out at the company's own plants in St. Petersburg and the Moscow region.
Комментарии